ATIBAR - Efficacy and Safety of Two Doses of AllerT in Patients Allergic to Birch Pollen
Status:
Completed
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
A multicentre, Double-blind, Placebo-Controlled, Randomized Trial to Assess the Efficacy and
Tolerability of Two Dosing Regimens of AllerT, a Combination of Contiguous Overlapping
Peptides Derived from Bet v 1, in Adults with Birch Pollen Allergic
Rhinitis/Rhinoconjunctivitis